Activity of ceftazidime-avibactam against clinical and isogenic laboratory Pseudomonas aeruginosa isolates expressing combinations of most relevant β-lactam resistance mechanisms

The activity of ceftazidime-avibactam was compared with that of ceftazidime alone and meropenem against a collection of 190 Pseudomonas aeruginosa clinical isolates recovered from a multicenter study of bloodstream infections. The addition of avibactam increased ceftazidime susceptibility in the com...

Descripción completa

Detalles Bibliográficos
Autores: Torrens, Gabriel, Cabot, Gabriel|||0000-0002-6452-9945, Ocampo-Sosa, Alain A.|||0000-0002-9104-3115, Conejo, M. Carmen, Zamorano, Laura, Navarro Risueño, Ferran|||0000-0002-4302-2838, Pascual Leone, Álvaro|||0000-0001-8975-0382, Martínez-Martínez, Luis, Oliver, Antonio|||0000-0001-9327-1894
Tipo de recurso: artículo
Fecha de publicación:2016
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:285169
Acceso en línea:https://ddd.uab.cat/record/285169
https://dx.doi.org/urn:doi:10.1128/AAC.01282-16
Access Level:acceso abierto
Palabra clave:SDG 3 - Good Health and Well-being
Descripción
Sumario:The activity of ceftazidime-avibactam was compared with that of ceftazidime alone and meropenem against a collection of 190 Pseudomonas aeruginosa clinical isolates recovered from a multicenter study of bloodstream infections. The addition of avibactam increased ceftazidime susceptibility in the complete collection of strains (64.7% to 91.1%) and particularly among subsets of isolates showing AmpC hyperproduction (10.9% to 76.1%) or multidrug resistance (MDR) profiles (27% to 77.8%). The MICs of ceftazidime-avibactam, in contrast with those of ceftazidime or meropenem, remained at ≤4 μg/ml for a panel of 16 P. aeruginosa PAO1 isogenic mutants expressing multiple combinations of the most relevant β-lactam resistance mechanisms.

Similares en LA Referencia